ISLET Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Classifies cadaveric human islets under the organ-procurement framework instead of drug, biologic, or tissue-product regulation and requires conforming HHS action.
Who Benefits and How
Islet-transplant programs and patients could face a clearer and potentially less burdensome pathway for procurement and transplantation.
Who Bears the Burden and How
HHS and FDA would have to revise regulations and oversight practices to fit the new legal classification.
Key Provisions
- Treats cadaveric human islets as organs for procurement purposes.
- Excludes those islets from specified drug, biologic, and tissue-product categories.
- Requires conforming regulation updates and a report.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Classifies cadaveric human islets under the organ-procurement framework instead of drug, biologic, or tissue-product regulation and requires conforming HHS action.
Key Policy Areas
Healthcare, Government Operations
Primary Purpose
Classifies cadaveric human islets under the organ-procurement framework instead of drug, biologic, or tissue-product regulation and requires conforming HHS action.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Islet-transplant programs and patients seeking broader transplant access
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal health regulators revising rules and oversight to reflect the new classification
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMr. Lee (for himself and Mr. Budd) introduced the following …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology